Cytovance Biologics expands analytical services offering for biotech and pharmaceutical customers. The US based contract development and manufacturing organization provides services to the biopharmaceutical industry. Now the company can offer analytical capabilities on a stand-alone basis without the need for a manufacturing engagement. This approach provides sponsors with direct access to Cytovance’s highly experienced analytical team and regulatory-ready solutions.
Cytovance has 20+ years of experience in biologics development and manufacturing programs. The company is now using that expertise to provide stand-alone analytical services to biopharmaceutical companies. This expanded offering meets an increasing demand for outsourced analytical support. It also provides customers with more flexibility in their development and manufacturing strategies.
Cytovance is available to clients for a variety of analytical activities. These services include analytical method development, transfer, qualification and validation. The portfolio includes product characterization and release testing. Furthermore customers can benefit from storage service and stability studies. This model allows sponsors to select services to meet their individual program needs. That means companies can tap into specialized analytical expertise without committing to a broader manufacturing project.
“Today’s biotechnology companies face increasing pressure to advance programs quickly while managing limited internal resources, evolving regulatory requirements, and increasingly complex development pathways,” said Ping Zhang, CEO of Cytovance Biologics. “By expanding our analytical services, we are providing sponsors with access to experienced scientists, robust analytical capabilities, and quality-driven processes that support informed decision-making throughout development. Our goal is to help clients move programs forward efficiently and with confidence.”
GMP and Non-GMP Testing Support Biologics Programs
Cytovance’s analytical services support programs from early development through to commercialization. The company offers these capabilities in both GMP and non-GMP environments. This flexibility can be a boon for emerging biotechnology companies that are lean on staff. They may also have some limited laboratory infrastructure.
Cytovance is a proven leader in analytical development and platform methodologies that clients rely on. These features may assist in expediting product characterization and development activities. As the programs progress, sponsors may move to GMP compliant testing and stability services. These services may also include regulatory submissions and process validation.
They can also help companies prepare for commercial readiness. Consequently, sponsors can access analytical support as their development needs become more advanced. The standalone model also supports companies seeking domestic analytical partners. U.S.-based testing capabilities can provide additional flexibility for organizations managing complex development programs.
“Our approach is centered on becoming a strategic analytical partner and an extension of our clients’ teams,” said Sudha Ankala, Ph.D., PMP, Senior Director of Program Management at Cytovance Biologics. “Whether a sponsor requires a single analytical study, ongoing stability support, or routine GMP testing, we provide scientific expertise, rapid communication and the flexibility needed to adapt to evolving program requirements and development timelines.”
Analytical Services Strengthen Biologics Development Support
The company expects demand for its analytical services based in the U.S. will increase, as biologics pipelines continue to grow. At the same time, many more organizations are seeking trusted domestic partners. Cytovance’s new offering reflects the evolving needs of the biopharmaceutical industry. We aim to provide flexible analytical support at different stages of development.
The stand-alone model also allows sponsors to tap into specific capabilities as needed. This approach can allow organizations to control their resources, while still being able to draw on specialized scientific expertise. The expanded analytical services portfolio also extends Cytovance’s support to biologics developers. Its activities cover development, testing, stability, characterization and regulatory focused activities.
Analytical testing remains a critical part of development as biologics programs become more complex. Companies need reliable data to make development decisions and to determine regulatory needs. Cytovance is marketing its analytical team as an extension of sponsor organizations. The company combines scientific expertise with both GMP and non-GMP capabilities.
Cytovance continues to support biotechnology and pharmaceutical companies with this expanded offering. Its independent analytical services provide an additional option for sponsors who need flexible development support. The launch reinforces Cytovance Biologics’ constant dedication to science-based solutions. It also speaks to the company’s commitment to support biologics programs from early development to commercialization.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
